(PDF) P2.13-13 Real-World Study of Osimertinib in EGFR

P2.13-13 Real-World Study of Osimertinib in EGFR T790m-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1408

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

Respiratory Medicine

English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Oncology Reports

Cancer Research

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancer Research

English

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Archivos de Bronconeumologia

Respiratory Medicine

English

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy, Safety, and Resistance Profile of Osimertinib in T790M Mutation-Positive Non-Small Cell Lung Cancer in Real-World Practice

Multidisciplinary

English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

Thoracic Cancer

Respiratory Medicine

English